MedTrace Logo

The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.

NCT02997722 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-06-02

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effect of ketamine on the treatment of patients hospitalized with suicidal thoughts. Half of the patients will receive one dose of ketamine in the vein. The other half will receive a placebo. Because we think that ketamine will improve depression and suicidal thoughts, we expect that patients who receive ketamine will require less time in the hospital than patients who receive placebo.

Conditions

Interventions

DRUG

Ketamine

IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.

DRUG

Normal Saline

IV infusion of 100 ml of normal saline over 45 minutes.

Sponsors & Collaborators

  • Allen Richert

    lead OTHER

Principal Investigators

  • Allen C Richert, MD · University of Mississippi Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-02
Primary Completion
2017-05-19
Completion
2017-05-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02997722 on ClinicalTrials.gov